24/05/2026
Элэгний Д вирүсийн эм албан ёсоор эмчилгээнд нэвтэрлээ. Манай улсад В вирүсийн архаг халдвартай хүмүүсийн 57 орчим хувь нь Д вирүсийн давхар халдвартай байдаг энэ хүмүүс илүү эрт, элэгний хорт хавдраар өвддөг.
Today, the FDA approved Hepcludex (bulevirtide-gmod) injection, the first FDA-approved treatment for chronic hepatitis delta virus (HDV) infection in adults. This approval fills a critical gap in care for patients who, until now, have had no FDA-approved therapies available to treat this serious and life-threatening condition. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-chronic-hepatitis-delta-virus-hdv-infection
Hepcludex was granted Breakthrough Therapy Designation and Orphan-Drug Designation. Hepcludex also received priority review and was approved under the Accelerated Approval pathway — reflecting the urgency and significance of this milestone.
Today's approval addresses a critical need for people with chronic HDV infection and builds on the FDA's commitment to advancing the health of all Americans.
